6533b829fe1ef96bd128ae2e
RESEARCH PRODUCT
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Anna Rita ScortechiniElisabetta AbruzzeseAlessandro MaggiLuigiana LucianoEmilia ScalzulliCristina BucelliBruno MartinoDaniele CattaneoImma AttolicoPatrizia PregnoAlessandra MalatoMario AnnunziataMassimo BrecciaAlessandra IurloAntonella GozziniGiovanni CaocciVincenzo Accursosubject
OncologyAdultMalemedicine.medical_specialtyAdolescentMyelogenouschemistry.chemical_compoundInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveMedicineHumansChildProtein Kinase Inhibitorsbusiness.industryPonatinibLow doseFollow up studiesImidazolesMyeloid leukemiaInfantHematologymedicine.diseasePyridazinesLeukemiachemistryChild PreschoolFemalebusinessFollow-Up Studiesyear | journal | country | edition | language |
---|---|---|---|---|
2020-07-07 | American journal of hematology |